Worries about a stricter US FDA come to nothing, as last year’s approval total beats 2019’s.
Bintrafusp alfa’s most important study, head to head against Keytruda in front-line lung cancer, is scrapped.
Non-Covid-19 medical device approvals tick up alongside the agency’s pandemic efforts.
The vast majority of industry-sponsored studies suspended because of Covid-19 resumed quickly, a new analysis finds.
Troriluzole has failed in an Alzheimer’s trial, reminding the markets that this is par for the course in this disease.
Aclaris takes a step towards an oral rheumatoid arthritis therapy.
Blockbuster sales are predicted for several projects nearing approval, from Biogen, Argenx, Fibrogen and others.
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
Positive surprises with Lexicon’s Zynquista and DBV’s Viaskin Peanut show that you can never entirely write biotech off.
The nascent company hopes to prove that its inhaled pan-Jak is best in class.
Pivotal data for JNJ-78436735 are imminent, with Novavax and Curevac not far behind.
Nantkwest claims efficacy with its most advanced NK cell therapy but, as ever with Patrick Soon-Shiong companies, it’s complicated.
In terms of private investments, 2020 was the year of the liquid biopsy.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
It takes more than a pandemic to stop medical device companies merging.
The pharma giant resorts to deal-making for a much-needed late-stage IO asset, leaving its own PD-1 agent out in the cold.
Waning factor VIII levels mean the durability question is still unanswered.
Pinpointing new forms of the coronavirus could be vital, particularly if it mutates in response to vaccination, the company says.
The Kymab takeover represents another bold move as the French company bids to rebuild its pipeline.
Donanemab’s apparent success in a mid-stage trial can be read as support for the beta-amyloid hypothesis, but the reality is more complex.